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GENERAL COMMENTS
The authors have attempted to characterised the pregnancy complications encountered by women with SLE when compared to women without SLE. I was hoping this study would assist in the validation of previous studies involving other national cohorts, but additional refinement needs to be done. There are significant omissions in the design which could lead to a flawed conclusion.
Firstly, how did the authors distinguish between a flare of SLE (e.g. lupus nephritis) versus pre-eclampsia. Both could potentially cause hypertension and proteinuria. This does not seem to have been defined. In fact, there does not seem to be a single case of flare of SLE in the study -which would be most unusual. A third of women with SLE flare in pregnancy. Flares would also contribute to the placentally-mediated adverse outcomes such as pre-eclampsia, SGA / IUGR and pre-term delivery, etc. This is a significant omission in the study design.
Moreover, the two most important determinants of the outcomes of a SLE pregnancy are: presence of anti-phospholipid syndrome (APS) and use of hydroxychloroquine in pregnancy. Both these variables are not captured in the data. These two variables should have also been included in the multivariate analysis. Women in the general population may also have primary APS.
Steroids contribute to a significant degree to preterm deliveries from preterm rupture of membranes, infection etc. Data on organ involvement in SLE e.g. lupus nephritis can also impact on pregnancy outcomes. This too has not been included. Additional data to characterise the SLE cohort is necessary.
Page 6: This is not a unique study and many such studies already exist in the literature. Therefore, the statements made on Page 6 lines 24-34 should be removed as the next sentence in the text contradicts this.
Some statements included are archaic e.g. the comment that SLE was viewed as a contraindication for pregnancy (page 6 line 14 to 16). This has not been practiced for the best part of the last half a century, and it is no longer inappropriate to be included in any scientific paper published in 2018.
Page 7 (and other sections): Spontaneous abortions were categorised as 0,1 and ≥2 -what do each of the categories mean? Is it the number of miscarriages?
The terminology 'drinker, 'smoker' are no longer considered politically correct. Would it be alcohol the 'drinkers' imbibe? Perhaps defining it as alcohol use of more than X units per week. Also 'lifestyle' was not adequately defined other than 'smoking and drinking'. For 'Therapeutic abortions' -could the authors please define the indications for it? It is too broadly defined in the definitions and further delineation of this would be most helpful.
Please include numbers who had a flare of SLE in pregnancy. This is crucial and needs to be adjusted for in the adjusted OR as they could significantly contribute to most of the adverse maternal and fetal outcomes listed in table 1 and 2. Comment 3: Clarify the protocol of patient care (frequency of medical appointments, evaluations, laboratory studies, etc.). Response: Our reasoning was similar to the response to comment 2. We added the following information to the methods section on page 6 line 2-3: "All participants with SLE were evaluated by an experienced gynecologist at least monthly and by a rheumatologist at least once per trimester. At each evaluation, a physical examination and laboratory tests were performed, and medications were adjusted as needed".
Comment 4: Usually, gestational loss is considered abortion before week 20, but the authors considered it before 28, clarifying it. Response: We used a Chinese definition. Although we truly realize that most of the definitions in other countries define abortion as occurring before 20 weeks, all text books and guidelines in China define abortion as fetal loss before 28 weeks (Xing Xie, et al. Obstetrics and Gynecology People's Medical Publishing House. 2013; 8th ed:47-50) . We admit that this discrepancy was a limitation and a source of bias when we compare our data with other international cohorts. Therefore, we further divided spontaneous abortions into those occurring at <10 weeks and ≥10 weeks. According to the definition of APS, these categories will help us identify the proportion of APS and the rate of early spontaneous abortion. Furthermore, here, we defined 'fetal loss' as all pregnancies that did not end with a live birth, including spontaneous abortions, therapeutic abortions, stillbirths or intrauterine fetal deaths. Thus, these definitions did not affect the calculations of the fetal loss rate and its odds ratio.
Comment 5: The drugs received by the patients during pregnancy (antimalarials, corticosteroids, immunosuppressants) should be noted.
Response: Yes, we completely agree with you. These data were had already been extracted from the medical records, and based on the reasoning described in the response to comment 2, we did not show them. We have added this information to the results section on page 15 line 13-20 and the discussion section on page 22 line 8-20, including the reference (Saavedra MA et al. Clin Rheumatol. 34(2015) 1211-6).
Comment 6: Specify the activity rate of SLE during pregnancy and postpartum. I consider it important because it is known that disease activity can influence the maternal-fetal outcome. (Saavedra MA et al., Lupus, 2015 Feb; 24 (2) : 180-5.) Response: Yes, we completely agree with your suggestion that disease activity can significantly influence the maternal-fetal outcomes. The rate of SLE activity was added to the results section on page14 line 7 and Table 2 . We also provided a better discussion of this topic in the discussion section on page 18 line14-19 and added (Saavedra MA et al., Lupus, 2015 Feb; 24 (2) : 180-5) as a reference.
Comment 7: Is the state of the autoantibodies of the patients known?
Response: Yes, these data were extracted from the medical records, and based on the reasoning described in the response to comment 2, we did not show them in the previous version. We have added this information to the results section on page 13 line 8-11 and Table 1 .
Comment 8: The authors state in the discussion that they found a higher cesarean section rate compared to previous studies. However, other cohort studies have already reported similar results (Saavedra MA et al., Rheumatol Int. 2016 Oct; 36 (10) : 1431-7.) Response: Yes, Prof. Saavedra, we completely agree with you. Your study also reported a high cesarean section rate (77.1-86.5%) in the SLE group in Mexico, a Latin American cohort. The incidence of cesarean section is increasing worldwide. Perhaps, as described in your article, this increase is due to sociocultural, economic, medical-legal, and biomedical factors, and in your health system, gynecologists could choose to operate on patients with the intent of preventing complications related to SLE, which is quite similar to the situation in China. I have already added your article as a reference and a comparison of your results to the discussion section on page 19 line 19-22. Thank you for the useful comments.
Response to Reviewer 2: Prof. Teh Cheng Lay
Comment 1: Characteristics of SLE patients should be elaborated especially with lupus nephritis involvement. Response: We greatly appreciate your comment, with which we completely agree. Actually these data were extracted from the medical records, and as this article focused on the comparison between women with and without SLE, we only showed the data and variables available for both groups. However, based on the reviewers' comments, we realized that this information was essential to show the specific characteristics of patients with SLE. We have added this information to the methods section on page 7 line 1-19, the results section on page 13 line 1-13and Table 1 .
Comment 2: Incidence of APS among the SLE cohort. Response: Our reasoning was the same as described in the response to comment 1. We have added this information to the methods section on page 7 line 9-10, the results section on page 13 Line 7and Table 1 .
Comment 3: Activity of SLE during the pregnancy. Response: Our reasoning was the same as described in the response to comment 1. We have added this information to the methods section on page 9 line 8-12, the results section on page 14 line 7 and Table 2 .
Comment 4: Incidence of neonatal lupus and incidence of anti Ro and La among the women with SLE.
Response: Only 2 cases of neonatal lupus were observed in the SLE group, both of which presented as mucocutaneous lesions. We added this information to the fetal outcomes section on page 7 line 5-9. We also added levels of all autoantibodies in patients to the results section on page 13 line 8-12and Table 1 .
Response to Reviewer 3: Prof. May Ching Soh Comment 1: Firstly, how did the authors distinguish between a flare of SLE (e.g. lupus nephritis) versus pre-eclampsia. Both could potentially cause hypertension and proteinuria. This does not seem to have been defined. In fact, there does not seem to be a single case of flare of SLE in the studywhich would be most unusual. A third of women with SLE flare in pregnancy. Flares would also contribute to the placentally-mediated adverse outcomes such as pre-eclampsia, SGA / IUGR and pre-term delivery, etc. This is a significant omission in the study design.
Response: We greatly appreciate your precise comments. First, 16% to 30% of pregnant women with SLE were affected by pre-eclampsia, and we admitted that the differentiation of this condition from lupus nephritis is difficult, as both conditions manifest as proteinuria, renal disorder, hypertension, and thrombocytopenia, and sometimes even co-exist. Although several guidelines or biomarkers, such as placental growth factor (PlGF) and vascular endothelial growth factor (VEGF), are available, they have limited utility in practical clinical settings. According to the international consensus for SLE flares (Ruperto N et al. Lupus. 20(2011) 453-62) , an SLE flare was defined as a measurable increase in disease activity in one or more organ systems involving new or worsening clinical signs and symptoms and/or laboratory measurements. The flare must be considered clinically significant by the assessor and a change or an increase in treatment is typically considered. In our study, we considered several clinical manifestations together, including onset time of hypertension, complement level, anti-dsDNA level, the erythrocyte sedimentation rate (ESR), involvement of other organs and even responses to steroids. This differential diagnosis was a comprehensive process, and it was always assessed by an experienced gynecologist or a rheumatologist in our study. We added the corresponding content to the method section on page 9 line 8-12.
Second, we completely agree with your comment that flares have a very important contribution to adverse pregnancy outcomes, but since the main object of this article is to compare pregnancy outcomes between women with and without SLE, we only focused on the data and variables available for both groups. Your point about the effect of SLE flares on pregnancy outcomes in the SLE group will be analyzed further in our next study. We added the SLE flare rate to the results section on page 14 line 7 and Table 1 of the revised manuscript.
Comment 2: Moreover, the two most important determinants of the outcomes of a SLE pregnancy are: presence of anti-phospholipid syndrome (APS) and use of hydroxychloroquine in pregnancy. Both these variables are not captured in the data. These two variables should have also been included in the multivariate analysis. Women in the general population may also have primary APS. Response: Actually, these data had already been extracted from the medical records, but as we mentioned above, the main object of this article was to compare pregnancy outcomes between women with and without SLE. Therefore, we only showed the data and variables available for both groups. However, based on your comments and the other reviewers' suggestions, we realized that this information was essential and important to show the specific characteristics of patients with SLE. Thus, we have added the APS rate and the medications to the results section on page 13 line 7, page 15 line 13-20 and Table 1 . As the prevalence of APS in general population is still unclear (Schreiber K et al. Nature Reviews Disease Primers. 4(2018) 17103) and only one published abstract estimated the APS incidence as 50/100,000 in the general population (Duarte-Garcia A et al. Arthritis and Rheumatology. 2017(69) S10), which is very low, we did not collected APS data from pregnant women without SLE, which was a limitation of our study design.
Comment 3: Steroids contribute to a significant degree to preterm deliveries from preterm rupture of membranes, infection etc. Data on organ involvement in SLE e.g. lupus nephritis can also impact on pregnancy outcomes. This too has not been included. Additional data to characterize the SLE cohort is necessary.
Response: Yes, we completely agree with your comment. As we mentioned above that the main object of this article was to compare pregnancy outcomes between women with and without SLE, we only showed the data and variables available for both groups. We did not show a sufficient amount of data for the SLE group. According to your valuable comments, we have added this information to the methods section on page 7 line 1-19, the results section on page 13 line 1-13and Table 1 .
Comment 4: Page 6: This is not a unique study and many such studies already exist in the literature. Therefore, the statements made on Page 6 lines 24-34 should be removed as the next sentence in the text contradicts this. Response: Thank you for this very good comment, which we truly appreciate. We changed the text on page 5 line 8-10 to "Although several studies have compared pregnancy outcomes between women with SLE and the general population3-6 and reported that SLE is associated with adverse obstetric outcomes, few studies have examined these outcomes in a Chinese cohort."
Comment 5: Some statements included are archaic e.g. the comment that SLE was viewed as a contraindication for pregnancy (page 6 line 14 to 16). This has not been practiced for the best part of the last half a century, and it is no longer inappropriate to be included in any scientific paper published in 2018. Response: We completely agree with your and changed the sentence on page5 line 5-7 to "As treatments for pregnant women with SLE have improved and increasingly involve multidisciplinary management, pregnancy outcomes have dramatically improved in recent decades." Comment 6: Page 7 (and other sections): Spontaneous abortions were categorized as 0,1 and ≥2 -what do each of the categories mean? Is it the number of miscarriages? Response: Yes, these values represent the number of the miscarriages experienced by women with a history of spontaneous abortion. We added a clarification to the methods and results section on page 6 line 19 and page12 line15-16, respectively.
Comment 7: The terminology 'drinker, 'smoker' are no longer considered politically correct. Would it be alcohol the 'drinkers' imbibe? Perhaps defining it as alcohol use of more than X units per week. Also 'lifestyle' was not adequately defined other than 'smoking and drinking'. Response: Yes, we completely agree with your comments. We changed the sentence on page 6 line 20-22 to "None of the women in the study population had ever smoked or used alcohol during pregnancy; therefore, these two variables were not included in the study." The majority of pregnant women in China do not drink or smoke during pregnancy. Regarding lifestyle, we did not collect sufficient data on factors such as daily activity, social work, education level, etc., which we plan to include in our next prospective study.
Comment 8: Page 8 Lines 21-22. Premature rupture of membranes (PROM) is internationally defined as rupture of membranes > 37 weeks gestation, prior to the onset of labour. Perhaps the more interesting variable to consider in the context of SLE would be -preterm PROM (PPROM). Response: Thank you for this very constructive comment. According to your comment, we have further divided PROM into TPROM (Term PROM) and PPROM (Preterm PROM). Originally, we did not observe a difference in PROM between the two groups, but in the sub-group analysis, patients with SLE had a higher risk of PPROM but not TPROM, a highly intriguing result. This information is presented in the method section on page 8 line16-19, the results section on page 14 line 2-5 and Table 2 .
Comment 9: Lines 40-41. Post-partum infection has been defined as any infection that occurs after childbirth. This can be very broad. Would an infection occurring 3 months post-partum also be included? Perhaps to give us a definition e.g. within 24 hours of delivery or within 10 days following delivery or miscarriage.
Response: We agree with you that this "postpartum infection definition" was too broad. We examined the literature and redefined this term using the WHO definition of "Infection of the genital tract occurring at any time between the onset of membrane rupture or labor and the 42nd postpartum day, in which two or more of the following symptoms are present: pelvic pain, fever, abnormal vaginal discharge, abnormal smell/foul odor discharge or delay in uterine involution" (WHO recommendations for prevention and treatment of maternal peripartum infections. Publication date: September 2015). We also reanalyzed the data, but the result did not change. This information is presented in the methods section on page 9 line 1-3.
Comment 10: Page 9 Lines 40. Preterm delivery -this is too broad a definition esp. in women with SLE who deliver early for a variety of reasons e.g. a flare of SLE, fetal growth restriction, etc. Categorizing preterm delivery according to WHO definitions would be more useful.
Response: According to the WHO, preterm delivery is defined as babies born alive before 37 weeks of pregnancy. Sub-categories of preterm birth are defined based on gestational age; here, we accepted your advice to further divided preterm into very preterm (28-32weeks) and moderate to late preterm (≥32 weeks), and both of the ORs remained significant after adjusting for confounding factors. This information is presented in the method section on page 10 line15-17, the results section on page 14 line 19-22 and Table 3 .
Comment 11: Page 10 Lines 8-9. Low birth weight (LBW) at < 2500g is a crude measure of outcomes. A 2500g 28 week infant may be acceptable. As SGA is already captured, I would suggest removing LBW.
Response: We agree with you and removed LBW.
Comment 12: Lines 13-14: Methods of deliveries should be further subdivided into: Caesarean sections (i) elective (can be by maternal choice), (ii) emergency and (ii) semi-urgent e.g. following failed induction of labour.
Response: This suggestion is good. We further divided cesarean section into elective and emergency cesarean section, according to the indications for cesarean section. Patients with SLE tended to undergo elective cesarean sections. This information has been added to the method section on page 10 line18-20, the results section on page14 Line22-page 15 line 1-2 and Table 3 .
Comment 13: Table1:'Spontaneous abortion' or perhaps spontaneous pregnancy losses could be further defined into ≤ 10 weeks and > 10 weeks. Mid-trimester losses are typical of women with APS and would be interesting to know what the numbers are. Response: We appreciate this very good suggestion and have further divided spontaneous abortion into those occurring at <10 weeks and ≥10 weeks. According to the definition of APS, the use of these categories will help us determine the proportion of APS and the rate of early spontaneous abortion. Furthermore, most of the spontaneous abortions occurred at ≥10 weeks, regardless of the group. This information is presented on method section page 9 Line21-22, result section page 14 Line 13-16 and Table 3 .
Comment 14: Table 2 : For 'Therapeutic abortions' -could the authors please define the indications for it? It is too broadly defined in the definitions and further delineation of this would be most helpful.
Response: Yes, therapeutic abortion was defined as abortion for therapeutic reasons because the pregnancy might be a threat to maternal health, such as a life-threatening SLE flare, other severe obstetric complications, including severe thrombocytopenia or HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, etc., or fetal lethal malformations, such as maldevelopment of the cardiac anatomy. This information is presented on page 10 Line 2-7.
Comment 15: Please include numbers who had a flare of SLE in pregnancy. This is crucial and needs to be adjusted for in the adjusted OR as they could significantly contribute to most of the adverse maternal and fetal outcomes listed in table 1 and 2. Response: We completely agree with you that flares have a very important contribution to the adverse maternal and fetal outcomes, but since the main object of this article was to compare pregnancy outcomes between women with and without SLE, as we mentioned above, we did not adjust for the flare factor in this study, as data for this variable was not available for both groups. Your suggestion about the effect of SLE flares on the pregnancy outcomes in the SLE group will be investigated in our next study. We added the SLE flare numbers and rates to the result section on page 14 Line 7 and Table 1 of the revised manuscript.
Comment 16: Table 3 : In general reporting stillbirths is sufficient. Presumably live births would be a sum total of cases after removing stillbirths and terminations of pregnancy -elective or otherwise.
Response: Here, we defined 'fetal loss' as all pregnancies that did not end with a live birth, including spontaneous abortions, therapeutic abortions, stillbirths or intrauterine fetal deaths, as shown in Table  3 . Therefore, the total number of pregnancies=fetal loss+live birth. The fetal loss number=spontaneous abortions+therapeutic abortions+stillbirths.
Comment 17: Caesarean sections need to be further categorised as per suggestion on page 10. The proportion of deliveries via caesarean section seems disproportionately high even in those without SLE (approximately 55.6% -is this normal for China? The international standards are between 20-30%) Response: Yes, this value is normal in China. As I mentioned in the article, this finding has several potential explanations, including a fear of pain and accidents during vaginal birth, an uneasy doctorpatient relationship, the profitability of caesarean sections for the hospital, and increases in the number of babies with macrosomia at birth and the number of pregnancies in older women (Mi J, Liu F. Lancet. 383(2014) 1463-4). Furthermore, Saavedra MA et al. (Saavedra MA et al., Rheumatol Int. 2016 Oct; 36 (10) : 1431-7) also reported a high cesarean rate (77.1-86.5%) in a Latin American SLE group, consistent with our result. The main explanations were Mexican sociocultural, economic, medical-legal, and biomedical factors.
Comment 18: I specifically have not commented on the discussion as I believe that further analysis and data collection is necessary. Additional data variables esp. inclusion of a flare of SLE, data on HCQ use etc. are likely to change the outcomes of this study and this can be reflected in an updated discussion.
Response: Thank you very much for the useful and precise comments. We have included additional data, which had actually already been extracted from the medical records. As mentioned above, the main objective of this article was to compare pregnancy outcomes between women with and without SLE; therefore, we only focused on the data and variables available for both cohorts and did not show some of the SLE characteristics in the last version. However, in this revised version, we show more complete data for the SLE group and performed additional analyses. Accordingly, we added new content to the discussion section; all of these changes to the revised manuscript are in red color in the marked copy. Thank you again for your attention and pertinent comments, as they greatly improved our manuscript. 
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GENERAL COMMENTS
Good effort
